Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Veloxis, Athena enter alliance for AtorFen drug
AtorFen contains the lowest fully effective dose of fenofibrate and is a combination of two dyslipidemia treatments in one tablet. The data from AtorFen’s study showed improvements in
AtorFen contains the lowest fully effective dose of fenofibrate and is a combination of two dyslipidemia treatments in one tablet. The data from AtorFen’s study showed improvements in
The BLA submission is backed by data from two Phase III trials involving 652 patients in the US and Europe. According to the company, ocriplasmin will be the
The Quad contains four Gilead compounds in a complete once-daily, single-tablet regimen that include elvitegravir; cobicistat, a boosting agent that enables elvitegravir once-daily dosing; and Truvada(R) (emtricitabine/tenofovir disoproxil
The AB-rated product is a therapeutically equivalent alternative to the antiepileptic Felbatol (a registered trademark of Meda Pharmaceuticals). The Amneal generic is available in two sizes, 8 fl
IPX066 is a patented extended release capsule formulation of carbidopa-levodopa (CD-LD), intended to maintain consistent plasma concentration of levodopa. The NDA includes data from three controlled Phase III
AZD1419 is a second-generation TLR-9 agonist for asthma. The cost of development will be fully funded by AstraZeneca, and Dynavax will receive payment of $2.6m to begin the
The ingredients by SourceOne comprise specialized formulations of EPA/DHA Omega-3 oils, Citrus Polymethoxylated Flavonoids, TocoSource Palm Tocotrienols, and VESIsorb (which is designed to enhance bioavailability of a variety
The randomized trial, called BATON-CRC, will enroll approximately 252 patients with no prior VEGF-targeted therapy at approximately 80 centers in the US, Canada, Australia and Europe, the company
GlaxoSmithKline will retain the existing rights for these products in countries outside the US. Terms of the agreement have not been disclosed. GSK will manufacture and supply Fortaz
Initiation of the trial entitles Dynavax to receive a $6m milestone payment from GlaxoSmithKline (GSK) under their worldwide strategic alliance. GSK has an exclusive option to obtain a